Semaglutide vs. Tirzepatide vs. Retatrutide: Which GLP-1 Is Right for You?
If you've been researching medical weight loss, you've probably encountered these three names: semaglutide, tirzepatide, and retatrutide. You may have also encountered a lot of conflicting information about which one is better, which one is stronger, and which one you should be asking for.
Here's my honest take. There is no universally best option. There is only the right option for a specific person at a specific point in their journey — and that determination should come from a clinical conversation, not a social media post or a wellness ad.
What I can do is explain what each medication actually does, how they differ, and what I consider when deciding which one to discuss with a patient. That way, when you come in for a consultation, you're not starting from zero.
How These Medications Work — The Mechanism
All three medications belong to a class of drugs that work through incretin hormone pathways — the system your body uses to regulate appetite, blood sugar, and digestion. These pathways involve hormones that your gut releases after eating to signal to your brain that food has been consumed. The medications mimic or amplify those signals, which is why patients consistently report feeling less hungry and more satisfied with smaller amounts of food.
The difference between the three medications is how many of these pathways they target — and that difference is clinically meaningful.
Semaglutide targets one pathway — the GLP-1 receptor. GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite, and improves insulin sensitivity. It was originally developed for type 2 diabetes and has since become one of the most widely studied weight loss medications available. Clinical trials show average weight loss in the range of 10 to 15 percent of body weight with consistent use and appropriate lifestyle support.
Tirzepatide targets two pathways — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP works differently from GLP-1 in that it also influences fat cell metabolism and may enhance the brain's response to satiety signals. The dual action tends to produce greater weight loss than semaglutide for most patients — trials have shown average losses of 15 to 20 percent of body weight, and some patients do significantly better than that. It also tends to be better tolerated by patients who experience significant nausea on semaglutide.
Retatrutide targets three pathways — GLP-1, GIP, and glucagon. The glucagon component adds a layer of direct metabolic stimulation — it promotes fat burning and increases energy expenditure in ways that the first two medications don't. Early clinical data on retatrutide shows weight loss outcomes that exceed both semaglutide and tirzepatide, with some trials reporting average losses approaching 25 percent of body weight. It is the newest of the three and carries the least long-term safety data, which is a relevant consideration in clinical decision-making.
What I Actually Think About When Choosing
The comparison above makes it sound simple — more pathways, more weight loss. But clinical practice is more nuanced than that, and there are several factors I weigh that don't show up in a head-to-head chart.
Starting point and goals. For a patient who needs moderate weight loss, has no history of GLP-1 use, and wants to start conservatively, semaglutide is often the right first step. It's well-understood, well-tolerated for most patients, and the clinical evidence base is the most mature. For a patient who has already tried semaglutide without adequate response, or who has more significant weight loss goals, tirzepatide is a natural next conversation.
Side effect tolerance. Nausea is the most common side effect across all three medications, and it's usually most pronounced during dose escalation. Tirzepatide generally produces less nausea than semaglutide in most patients, which matters significantly for adherence. Retatrutide's side effect profile is still being characterized at a population level.
Muscle preservation — the thing most people aren't told. This is the piece I feel most strongly about, and it's almost never discussed in the online conversations about these medications. All three work partly by reducing appetite. Reduced appetite usually means reduced protein intake. Reduced protein intake means muscle loss — and as we covered in an earlier post, muscle loss directly undermines your metabolism in ways that follow you long after the medication ends.
Every patient at NOVA on a GLP-1 medication gets specific protein targets and resistance training guidance. This is not optional. It is the part that determines whether your results last.
Retatrutide and dopamine — something worth knowing. Because retatrutide acts on the glucagon pathway in addition to the other two, it can affect dopamine-related signaling in ways that semaglutide and tirzepatide typically do not. Some patients on retatrutide notice changes in motivation, drive, or libido that trace back to this mechanism. It's not universal, and it's manageable — but it requires monitoring SHBG and hormone levels alongside the standard metabolic markers. This is one reason that a medication this powerful belongs inside a supervised clinical relationship, not a telehealth subscription.
Labs before, during, and after. This applies to all three. Before starting, I want to see fasting insulin, HbA1c, thyroid function, liver markers, and a hormone panel. During treatment, we track how your body is responding — not just the scale, but metabolic markers, body composition, and hormone levels. After reaching your goal, the transition plan matters as much as the protocol itself. Stopping these medications without a maintenance strategy is how the weight comes back.
A Note on What These Medications Are Not
They are not a substitute for lifestyle. They are not a permanent fix on their own. They are not appropriate for everyone — there are contraindications involving thyroid history, pancreatitis, and other medical conditions that require careful screening before any prescription is written.
What they are, when used correctly, is genuinely remarkable. The mechanism by which they reduce hunger is different from willpower — they actually change the hormonal signals driving appetite in ways that make healthy choices easier than they have ever been for many patients. That is a meaningful clinical tool when it's deployed thoughtfully.
The patients I see who get the best long-term results are the ones who treat the medication as a window — a period when appetite is managed enough that they can build the habits, the muscle, and the metabolic foundation that will hold their results after the medication is no longer needed or is stepped down.
That's the version of medical weight loss we practice at NOVA Wellness. Not a prescription and a monthly check-in. A plan.
If you've been considering a GLP-1 medication and want to understand which option makes sense for your specific situation, that conversation starts with a free 30-minute consultation. Book at novawellnessut.com or call and text us at (801) 449-1402.
Matt Nelson, NP
NOVA Wellness — Orem, Utah
(801) 449-1402 · novawellnessut.com
